Mildred Lopez Garrido
Payments from drug & device makers
Across 116 payments — averaging $55.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$3K
- Janssen Research & Development, LLC$1K
- GSK$302
- Lilly USA, LLC$292
- AstraZeneca$234
- Boehringer Ingelheim$192
- plus $1K from 16 others
What the payments were for
- Travel & lodging$3,50254%
- Food & beverage$2,87544%
- Education$1002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 5 | $3,403 |
| Janssen Research & Development, LLC | 8 | $1,021 |
| GSK | 17 | $302 |
| Lilly USA, LLC | 15 | $292 |
| AstraZeneca | 13 | $234 |
| Boehringer Ingelheim | 9 | $192 |
| Amgen | 11 | $188 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $150 |
| Pfizer | 6 | $125 |
| Astellas Pharma US Inc | 2 | $116 |
| Novo Nordisk | 5 | $103 |
| Bayer | 3 | $72 |
| AbbVie | 3 | $49 |
| Exact Sciences | 3 | $47 |
| Shield Therapeutics Inc | 2 | $41 |
| Johnson & Johnson | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Lucid Diagnostics Inc. | 1 | $23 |
| Stryker | 1 | $20 |
| Novartis | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Neurelis, Inc. | 1 | $17 |
How this compares
$6,477 in reported general payments places this provider in the 90th percentile of 2,031 medical providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 40 | $37,306 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $24,247 |
| OzempicSemaglutide | 13 | $22,010 |
| TrulicityDulaglutide | 14 | $14,763 |
| Wixela InhubFluticasone Propion/Salmeterol | 27 | $5,629 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 76 | $2,351 |
| Atorvastatin Calcium | 166 | $1,403 |
| LantusInsulin Glargine,hum.Rec.Anlog | 11 | $1,354 |
| Glipizide ErGlipizide | 69 | $1,352 |
| Nifedipine ErNifedipine | 50 | $1,162 |
| Levothyroxine Sodium | 76 | $959 |
| Rosuvastatin Calcium | 96 | $879 |
| Fluticasone Propionate | 73 | $829 |
| Losartan Potassium | 86 | $717 |
| Irbesartan | 28 | $662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $125 | $37,30640 claims |
| GSKTrelegy Ellipta | $302 | $24,24720 claims |
| Novo NordiskOzempic | $103 | $22,01013 claims |
| Lilly USA, LLCTrulicity | $292 | $14,76314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,031 medical providers in Florida.
Other medical in Tampa
- Sandra SnyderTampa$156K
- Christopher RayTampa$41K
- Kathryn KlossTampa$33K
- Susan FerreyTampa$16K
- Gary RubinRockledge$2.1M
- Shanna MirantiNaples$415K
- Krystie LennoxBoca Raton$245K
- Jihan RamadanWellington$238K
- Ilanit SamuelsMiami$211K
- Erin DouceyWinter Haven$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.